Business Description
Omega Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US68217N1054
Description
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.57 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 2.21 | |||||
| Debt-to-EBITDA | -1.37 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.95 | |||||
| Beneish M-Score | -0.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -25.1 | |||||
| 3-Year EPS without NRI Growth Rate | -23.9 | |||||
| 3-Year FCF Growth Rate | -24.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.94 | |||||
| 9-Day RSI | 23.5 | |||||
| 14-Day RSI | 28.32 | |||||
| 6-1 Month Momentum % | 114.56 | |||||
| 12-1 Month Momentum % | -50.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.35 | |||||
| Quick Ratio | 3.35 | |||||
| Cash Ratio | 2.74 | |||||
| Days Sales Outstanding | 208.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21 | |||||
| Shareholder Yield % | -90.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3239.42 | |||||
| Net Margin % | -3147.92 | |||||
| FCF Margin % | -2956.7 | |||||
| ROE % | -106.14 | |||||
| ROA % | -51.09 | |||||
| ROIC % | -115.52 | |||||
| ROC (Joel Greenblatt) % | -141.66 | |||||
| ROCE % | -60.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 41.05 | |||||
| PB Ratio | 2.16 | |||||
| Price-to-Tangible-Book | 2.16 | |||||
| EV-to-EBIT | -1.84 | |||||
| EV-to-EBITDA | -1.97 | |||||
| EV-to-Revenue | 59.65 | |||||
| EV-to-Forward-Revenue | 53 | |||||
| EV-to-FCF | -2.02 | |||||
| Earnings Yield (Greenblatt) % | -54.35 | |||||
| FCF Yield % | -73.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OMGA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Omega Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.095 | ||
| EPS (TTM) ($) | -1.8 | ||
| Beta | 0 | ||
| Volatility % | 113.74 | ||
| 14-Day RSI | 28.32 | ||
| 14-Day ATR ($) | 0.200934 | ||
| 20-Day SMA ($) | 2.69 | ||
| 12-1 Month Momentum % | -50.73 | ||
| 52-Week Range ($) | 1.3 - 10.09 | ||
| Shares Outstanding (Mil) | 55.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Omega Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Omega Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Omega Therapeutics Inc Frequently Asked Questions
What is Omega Therapeutics Inc(OMGA)'s stock price today?
The current price of OMGA is $2.27. The 52 week high of OMGA is $10.09 and 52 week low is $1.30.
When is next earnings date of Omega Therapeutics Inc(OMGA)?
The next earnings date of Omega Therapeutics Inc(OMGA) is 2024-05-03 Est..
Does Omega Therapeutics Inc(OMGA) pay dividends? If so, how much?
Omega Therapeutics Inc(OMGA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers